|Videos|February 24, 2023
Emerging Therapies for Lower-Risk MDS
Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.
Advertisement
Episodes in this series
Data from the following clinical trials are discussed:
- 3076: Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
- 459: Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
- 1773: A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
- 4411: A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- 461: ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
Advertisement
Related to this article
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5